Akebia Therapeutics (AKBA) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 4.1% versus a loss of 71.4%. Over five years, IFRX leads with a -38.1% price change compared with -71.4% for AKBA. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $225.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | IFRX |
|---|---|---|
| Share price | $0.8148 | $1.53 |
| Market cap | $225.79M | $225.47M |
| 1-day change | -6.71% | -1.92% |
| YTD return | -49.39% | +51.49% |
| 1-year return | -71.41% | +4.08% |
| 5-year return | -71.41% | -38.06% |
| EPS (TTM) | $-0.12 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $2.95 |
| 52-week low | $0.814 | $0.798 |
| Distance from 52-week high | -74.54% | -48.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.10% | +400.65% |
| Average volume | 6.13M | 794.10K |
| Shares outstanding | 277.11M | 147.37M |
| Employees | 194 | 65 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed AKBA by 75.5 percentage points over the past year.
- The two companies sit in different sectors: Akebia Therapeutics in Health Care and InflaRx N.V. in Healthcare.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
AKBA vs IFRX FAQ
Which is bigger, Akebia Therapeutics or InflaRx N.V.?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $225.47M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, AKBA or IFRX?
IFRX returned +4.08% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and InflaRx N.V. in the same industry?
No. Akebia Therapeutics is in the Health Care sector, while InflaRx N.V. is in Healthcare.